-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse Börse FrankfurtISIN US60468T1051-
MIRATI THERAPEUTIC COM NPVBörse Börse FrankfurtISIN US60468T1051Symbol 26M
-
Mirati Therapeutics IncBörse Börse BerlinSymbol 26M
-
MIRATI THERAPEUTICS INCBörse Gettex System der Börse MünchenSymbol 26M
-
MIRATI THERAPEUTICS INCBörse Tradegate System der Deutsche Börse AG (60%)Symbol 26M
-
MIRATI THERAPEUTICS INCBörse Börse StuttgartSymbol 26M
-
ISIN US60468T1051 WKN: A1W1XVSymbol MRTX
-
EUR
-
Symbol 26M
-
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
10.034.599.936 oder 6.524.000.000
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
111 oder 587 Mitarbeiter
Mirati Therapeutics Inc outperformed den DAX um +946 % vom 14.05.2014 bis 25.06.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 124,7 EUR -1,42%
Entdecke die 6 ETFs in denen Mirati Therapeutics, Inc am höchsten gewichtet ist Insgesamt in 8 ETFs enthalten
Dir gefallen die Informationen zu Mirati Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Mirati Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu Mirati Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu Mirati Therapeutics Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
25 News & Informationen zur Mirati Therapeutics Inc Aktie
BeiGene : U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenstr? Macroglobulinemia
This marks the second FDA approval for BRUKINSA and its third approval in Waldenstr?8217;s macroglobulinemia globally
The approval is based on Phase 3 ASPEN trial comparing BRUKINSA against… | September 1, 2021
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval In Waldenström's Macroglobulinemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today
Aviva Holdings Ltd. Buys Pampa Energia SA
GuruFocus Article or News written by insider and the topic is about:
Armistice Capital, Llc Buys Iovance Biotherapeutics Inc, Burlington Stores Inc, Travere Therapeutics Inc, Sells TJX Inc, Lantheus Holdings Inc, Advance Auto Parts Inc
GuruFocus Article or News written by insider and the topic is about:
BeiGene Announces Acceptance Of A Supplemental Biologics License Application In China For Tislelizumab In Nasopharyngeal Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today
BeiGene : and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma (Form 8-K)
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® for Patients with High-Risk Neuroblastoma
CAMBRIDGE, Mass., BEIJING, China, and HEMEL… | August 19, 2021
Fairmount Funds Management LLC Buys Instil Bio Inc, Zogenix Inc, Insmed Inc, Sells Mirati Therapeutics Inc, Seres Therapeutics Inc, Trillium Therapeutics Inc
GuruFocus Article or News written by insider and the topic is about:
Handelsinvest Investeringsforvaltning Buys Crown Holdings Inc, Overstock.com Inc, TripAdvisor Inc, Sells Nuance Communications Inc, Proofpoint Inc, Redfin Corp
GuruFocus Article or News written by insider and the topic is about:
It’s Time To Own Mirati Therapeutics Stock (NASDAQ:MRTX)
For a while at least. The last time completed a set of 37 priors over the most recent 5 years which produced 33 (89%) winners.
Is Kingsoft Cloud Holdings Limited (KC) A Good Stock To Buy?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors…
BeiGene Announces Approval In Canada Of BRUKINSA® (Zanubrutinib) For The Treatment Of Patients With Mantle Cell Lymphoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve
Hedge Funds Are Buying West Fraser Timber Co. Ltd. (WFG)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first…
Is Vornado Realty Trust (VNO) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
BeiGene : Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
BeiGene, Ltd. , a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration has… | July 9, 2021
BeiGene Announces Acceptance Of A Supplemental Biologics License Application In China For Tislelizumab In Esophageal Squamous Cell Carcinoma (ESCC)
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today
Intellia Shares Soar on Positive Test Results
GuruFocus Article or News written by Barry Cohen and the topic is about: Merck, Sanofi, Gilead and others stand to benefit from clinical trials
Where Do Hedge Funds Stand On Alleghany Corporation (Y)?
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting…
A Peek Into The Markets: US Stock Futures Up Following Thursday's Rally; Nike Posts Upbeat Results
Pre-open movers
U.S. stock futures traded higher in early pre-market trade. The Dow Jones surged more than 300 points, while the S&P 500 closed at a …
Mirati Therapeutics' Adagrasib Gets Breakthrough Therapy Designation
(RTTNews) – Shares of Mirati Therapeutics, Inc. (MRTX) gained nearly 5% in extended trading session on Thursday after the clinical-stage oncology …
Mirati Therapeutics Inc (MRTX) Presents at AACR Virtual Meeting 2021 – Slideshow (NASDAQ:MRTX)
The following slide deck was published by Mirati Therapeutics, Inc.
BeiGene : Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1/L1 inhibitors and platinum-resistant ovarian cancer in an… | April 11, 2021
BeiGene Presents Clinical Data On Sitravatinib In Combination With Tislelizumab At The AACR Annual Meeting 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide,
Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc. By Investing.com
Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc.
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ –?Mirati Therapeutics, Inc. , a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San…
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare…